CLZ-8
Product Specifications
UNSPSC Description
CLZ-8 (Compound 8) is an orally active Mcl-1-PUMA interface inhibitor, with a Ki of 0.3 μM. CLZ-8 exhibits dual activity on reduce PUMA-dependent apoptosis while deactivating Mcl-1-mediated anti-apoptosis in cancer cells[1].
Target Antigen
Apoptosis; Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/clz-8.html
Purity
99.85
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1N=C(N2CCN(CCO)CC2)S/C1=C\C3=CC=C(C4=CC=CC=C4)C=C3
Molecular Weight
393.50
References & Citations
[1]Liu J, et al. Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound. Oncotarget. 2017 Apr 20;8(33):54236-54242.|[2]Feng T, et al. CLZ-8, a potent small-molecular compound, protects radiation-induced damages both in vitro and in vivo. Environ Toxicol Pharmacol. 2018 Jul;61:44-51.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-122627/CLZ-8-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-122627/CLZ-8-SDS-MedChemExpress.pdf
Clinical Information
No Development Reported
CAS Number
678158-55-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
